Autism Spectrum Disorder
Conditions
Interventions
Sponsors
Gillberg Neuropsychiatry Centre
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Autism Spectrum Disorder Age 12-40 years old. Are the trial subjects under 18? yes Number of subjects for this age range: 25 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 25 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Long QT syndrome Intellectual disability
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To test the Excitatory/Inhibitory (E/I) imbalance hypothesis of the underlying neurophysiology in Autism Spectrum Disorder, by testing the effect of the diuretic drug Bumetanide on objectively measured performances and physiological reactions to specific socio-emotional and perceptual tests. ;Secondary Objective: To test the safety and tolerability of the drug in Autism Spectrum Disorder. ;Primary end point(s): Improvement in emotion labeling task;Timepoint(s) of evaluation of this end point: Baseline, at 3 months and at 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Change in pupillary reaction to emotional faces Change in results in paradoxical motion perception task Change in attention to details Change in fear detection task Change in sensory perception Type of AE, SAEs, SUSARs Frequency of AE, SAEs, SUSARs Severity of AEs, SAEs ;Timepoint(s) of evaluation of this end point: Baseline, at 3 months and at 6 months. Safety endpoints regarding adverse events will be estimated at each contact with subjects. | — |
Countries
Sweden
Contacts
Public ContactGNC
Gillberg Neuropsychiatry Centre
Outcome results
None listed